{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T22:50:17Z","timestamp":1775170217020,"version":"3.50.1"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,29]],"date-time":"2022-08-29T00:00:00Z","timestamp":1661731200000},"content-version":"vor","delay-in-days":240,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Therapeutic Research"],"published-print":{"date-parts":[[2022]]},"DOI":"10.1016\/j.curtheres.2022.100684","type":"journal-article","created":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T01:39:08Z","timestamp":1661996348000},"page":"100684","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Modulation of Plasma 25-Hydroxyvitamin D3 Level by Imatinib Mesylate in Patients with Chronic Myelogenous Leukemia: The Role of Uptake and Efflux Transporters"],"prefix":"10.1016","volume":"97","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1643-0104","authenticated-orcid":false,"given":"Mervat M.","family":"Omran","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samia A.","family":"Shouman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raafat","family":"Abdelfattah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heba S.","family":"Moussa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadia A.","family":"Thabet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marwa S.","family":"Hamza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.curtheres.2022.100684_bib0001","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1182\/blood-2011-10-380774","article-title":"How I treat childhood CML","volume":"119","author":"Andolina","year":"2012","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.curtheres.2022.100684_bib0002","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1002\/pbc.24397","article-title":"Growth failure in children with chronic myeloid leukemia receiving imatinib is due to disruption of GH\/IGF-1 axis","volume":"60","author":"Narayanan","year":"2013","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"10.1016\/j.curtheres.2022.100684_bib0003","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.jpeds.2011.03.046","article-title":"Distinct impact of imatinib on growth at prepubertal and pubertal ages of children with chronic myeloid leukemia","volume":"159","author":"Shima","year":"2011","journal-title":"J Pediatr"},{"issue":"12","key":"10.1016\/j.curtheres.2022.100684_bib0004","doi-asserted-by":"crossref","first-page":"Cr721","DOI":"10.12659\/MSM.883599","article-title":"Changes in bone metabolic parameters in children with chronic myeloid leukemia on imatinib treatment","volume":"18","author":"Jaeger","year":"2012","journal-title":"Med Sci Monit"},{"issue":"3","key":"10.1016\/j.curtheres.2022.100684_bib0005","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/ped.13136","article-title":"Adverse effects of imatinib in children with chronic myelogenous leukemia","volume":"59","author":"Choeyprasert","year":"2017","journal-title":"Pediatr Int"},{"issue":"11","key":"10.1016\/j.curtheres.2022.100684_bib0006","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.tips.2016.08.003","article-title":"Impact of Membrane Drug Transporters on Resistance to Small-Molecule Tyrosine Kinase Inhibitors","volume":"37","author":"Neul","year":"2016","journal-title":"Trends Pharmacol Sci"},{"issue":"6","key":"10.1016\/j.curtheres.2022.100684_bib0007","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/FPC.0000000000000279","article-title":"PharmGKB summary: sorafenib pathways","volume":"27","author":"Gong","year":"2017","journal-title":"Pharmacogenet Genomics"},{"issue":"4","key":"10.1016\/j.curtheres.2022.100684_bib0008","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.3892\/mmr.2014.3074","article-title":"Inhibitory effects of imatinib on vitamin D\u2083 synthesis in human keratinocytes","volume":"11","author":"Mehlig","year":"2015","journal-title":"Mol Med Rep"},{"issue":"3","key":"10.1016\/j.curtheres.2022.100684_bib0009","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.chembiol.2013.12.016","article-title":"Vitamin D metabolism, mechanism of action, and clinical applications","volume":"21","author":"Bikle","year":"2014","journal-title":"Chem Biol"},{"issue":"12","key":"10.1016\/j.curtheres.2022.100684_bib0010","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1182\/blood-2003-12-4276","article-title":"Active transport of imatinib into and out of cells: implications for drug resistance","volume":"104","author":"Thomas","year":"2004","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.curtheres.2022.100684_bib0011","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1158\/1078-0432.CCR-07-4913","article-title":"Interaction of imatinib with human organic ion carriers","volume":"14","author":"Hu","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.curtheres.2022.100684_bib0012","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1124\/jpet.108.149815","article-title":"Up-regulation of transporters and enzymes by the vitamin D receptor ligands, 1alpha,25-dihydroxyvitamin D3 and vitamin D analogs, in the Caco-2 cell monolayer","volume":"330","author":"Fan","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"10.1016\/j.curtheres.2022.100684_bib0013","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1093\/epirev\/mxx005","article-title":"Vitamin D and Cancer Risk and Mortality: State of the Science, Gaps, and Challenges","volume":"39","author":"Mondul","year":"2017","journal-title":"Epidemiol Rev"},{"issue":"5","key":"10.1016\/j.curtheres.2022.100684_bib0014","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1159\/000374007","article-title":"Serum 25-Hydroxyvitamin D Levels and Prognosis in Hematological Malignancies: A Systematic Review and Meta-Analysis","volume":"35","author":"Wang","year":"2015","journal-title":"Cellular Physiology and Biochemistry"},{"issue":"3","key":"10.1016\/j.curtheres.2022.100684_bib0015","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/ejh.12818","article-title":"Vitamin D in hematological disorders and malignancies","volume":"98","author":"Kulling","year":"2017","journal-title":"European Journal of Haematology"},{"issue":"2","key":"10.1016\/j.curtheres.2022.100684_bib0016","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.clnu.2016.01.021","article-title":"Low serum vitamin D levels are associated with shorter survival after first-line azacitidine treatment in patients with myelodysplastic syndrome and secondary oligoblastic acute myeloid leukemia","volume":"36","author":"Radujkovic","year":"2017","journal-title":"Clinical Nutrition"},{"issue":"3","key":"10.1016\/j.curtheres.2022.100684_bib0017","doi-asserted-by":"crossref","first-page":"827","DOI":"10.3945\/ajcn.112.054676","article-title":"Plasma 25-hydroxyvitamin D concentration and lymphoma risk: results of the European Prospective Investigation into Cancer and Nutrition","volume":"98","author":"\u0141uczy\u0144ska","year":"2013","journal-title":"Am J Clin Nutr"},{"issue":"2","key":"10.1016\/j.curtheres.2022.100684_bib0018","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s00384-008-0593-y","article-title":"Chemotherapy is linked to severe vitamin D deficiency in patients with colorectal cancer","volume":"24","author":"Fakih","year":"2009","journal-title":"International journal of colorectal disease"},{"issue":"5","key":"10.1016\/j.curtheres.2022.100684_bib0019","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1179\/102453311X13085644679908","article-title":"Serum 25-hydroxyvitamin D levels are associated with prognosis in hematological malignancies","volume":"16","author":"Thomas","year":"2011","journal-title":"Hematology"},{"key":"10.1016\/j.curtheres.2022.100684_bib0020","first-page":"10","article-title":"Association of the Trough, Peak\/Trough Ratio of Imatinib, Pyridine\u2013N-Oxide Imatinib and ABCG2 SNPs 34 G>A and SLCO1B3 334 T>G With Imatinib Response in Egyptian Chronic Myeloid Leukemia Patients","author":"Omran","year":"2020","journal-title":"Frontiers in Oncology"},{"issue":"6","key":"10.1016\/j.curtheres.2022.100684_bib0021","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.curtheres.2022.100684_bib0022","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1210\/jc.2011-0385","article-title":"Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline","volume":"96","author":"Holick","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.curtheres.2022.100684_bib0023","doi-asserted-by":"crossref","first-page":"47","DOI":"10.4103\/1110-1067.139757","article-title":"Serum 25-hydroxyvitamin D levels in relation to disease status and prognosis in acute myeloid leukemia","volume":"39","author":"Elkerdany","year":"2014","journal-title":"The Egyptian Journal of Haematology"},{"issue":"4","key":"10.1016\/j.curtheres.2022.100684_bib0024","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/cncr.28368","article-title":"Low 25(OH) vitamin D3 levels are associated with adverse outcome in newly diagnosed, intensively treated adult acute myeloid leukemia","volume":"120","author":"Lee","year":"2014","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.curtheres.2022.100684_bib0025","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1159\/000374007","article-title":"Serum 25-hydroxyvitamin D levels and prognosis in hematological malignancies: a systematic review and meta-analysis","volume":"35","author":"Wang","year":"2015","journal-title":"Cell Physiol Biochem"},{"issue":"4","key":"10.1016\/j.curtheres.2022.100684_bib0026","first-page":"485","article-title":"Vitamin D in childhood cancer: a promising anticancer agent?","volume":"10","author":"Genc","year":"2013","journal-title":"Pediatr Endocrinol Rev"},{"issue":"5","key":"10.1016\/j.curtheres.2022.100684_bib0027","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1124\/dmd.117.078881","article-title":"Hepatic Transport of 25-Hydroxyvitamin D(3) Conjugates: A Mechanism of 25-Hydroxyvitamin D(3) Delivery to the Intestinal Tract","volume":"46","author":"Gao","year":"2018","journal-title":"Drug Metab Dispos"},{"issue":"11","key":"10.1016\/j.curtheres.2022.100684_bib0028","doi-asserted-by":"crossref","first-page":"27191","DOI":"10.3390\/ijms161126016","article-title":"Vitamin D Analogs Potentiate the Antitumor Effect of Imatinib Mesylate in a Human A549 Lung Tumor Model","volume":"16","author":"Maj","year":"2015","journal-title":"International journal of molecular sciences"},{"issue":"8","key":"10.1016\/j.curtheres.2022.100684_bib0029","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1007\/s11739-018-1957-0","article-title":"Vitamin D and tyrosine kinase inhibitors in chronic myeloid leukemia","volume":"13","author":"Campiotti","year":"2018","journal-title":"Internal and Emergency Medicine"},{"issue":"2","key":"10.1016\/j.curtheres.2022.100684_bib0030","doi-asserted-by":"crossref","first-page":"252","DOI":"10.2105\/AJPH.2004.045260","article-title":"The role of vitamin D in cancer prevention","volume":"96","author":"Garland","year":"2006","journal-title":"Am J Public Health"},{"issue":"2","key":"10.1016\/j.curtheres.2022.100684_bib0031","first-page":"149","article-title":"Vitamin D3 from sunlight may improve the prognosis of breast-, colon- and prostate cancer (Norway)","volume":"15","author":"Robsahm","year":"2004","journal-title":"Cancer Causes Control"},{"issue":"5","key":"10.1016\/j.curtheres.2022.100684_bib0032","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1200\/JCO.2006.07.5358","article-title":"Circulating 25-hydroxyvitamin D levels predict survival in early-stage non-small-cell lung cancer patients","volume":"25","author":"Zhou","year":"2007","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.curtheres.2022.100684_bib0033","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1093\/jnci\/djj101","article-title":"Prospective study of predictors of vitamin D status and cancer incidence and mortality in men","volume":"98","author":"Giovannucci","year":"2006","journal-title":"J Natl Cancer Inst"},{"issue":"1-2","key":"10.1016\/j.curtheres.2022.100684_bib0034","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jsbmb.2005.06.018","article-title":"Vitamin D and prevention of colorectal cancer","volume":"97","author":"Gorham","year":"2005","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"9","key":"10.1016\/j.curtheres.2022.100684_bib0035","first-page":"847","article-title":"Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland)","volume":"11","author":"Ahonen","year":"2000","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.curtheres.2022.100684_bib0036","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1093\/jnci\/djm204","article-title":"Prospective study of serum vitamin D and cancer mortality in the United States","volume":"99","author":"Freedman","year":"2007","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.curtheres.2022.100684_bib0037","doi-asserted-by":"crossref","first-page":"292","DOI":"10.4158\/EP.10.3.292","article-title":"Prevalence of vitamin D deficiency in patients attending an outpatient cancer care clinic in Boston","volume":"10","author":"Tangpricha","year":"2004","journal-title":"Endocrine practice: official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists"},{"issue":"8","key":"10.1016\/j.curtheres.2022.100684_bib0038","doi-asserted-by":"crossref","first-page":"4990","DOI":"10.1073\/pnas.78.8.4990","article-title":"Differentiation of mouse myeloid leukemia cells induced by 1 alpha,25-dihydroxyvitamin D3","volume":"78","author":"Abe","year":"1981","journal-title":"Proc Natl Acad Sci U S A,"},{"issue":"1","key":"10.1016\/j.curtheres.2022.100684_bib0039","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1073\/pnas.80.1.201","article-title":"1 alpha,25-Dihydroxyvitamin D3 and 1 alpha-hydroxyvitamin D3 prolong survival time of mice inoculated with myeloid leukemia cells","volume":"80","author":"Honma","year":"1983","journal-title":"Proc Natl Acad Sci U S A,"},{"issue":"9","key":"10.1016\/j.curtheres.2022.100684_bib0040","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1038\/nrc2196","article-title":"Vitamin D signalling pathways in cancer: potential for anticancer therapeutics","volume":"7","author":"Deeb","year":"2007","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"10.1016\/j.curtheres.2022.100684_bib0041","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1038\/sj.bjc.6601161","article-title":"1alpha,25-dihydroxyvitamin D(3) (calcitriol) and its analogue, 19-nor-1alpha,25(OH)(2)D(2), potentiate the effects of ionising radiation on human prostate cancer cells","volume":"89","author":"Dunlap","year":"2003","journal-title":"British journal of cancer"},{"issue":"5","key":"10.1016\/j.curtheres.2022.100684_bib0042","first-page":"321","article-title":"Long-term clinical remission of chronic lymphocytic leukaemia by dietary means","volume":"95","author":"Politzer","year":"2005","journal-title":"S Afr Med J"}],"container-title":["Current Therapeutic Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0011393X22000236?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0011393X22000236?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T00:59:43Z","timestamp":1757897983000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0011393X22000236"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":42,"alternative-id":["S0011393X22000236"],"URL":"https:\/\/doi.org\/10.1016\/j.curtheres.2022.100684","relation":{},"ISSN":["0011-393X"],"issn-type":[{"value":"0011-393X","type":"print"}],"subject":[],"published":{"date-parts":[[2022]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Modulation of Plasma 25-Hydroxyvitamin D3 Level by Imatinib Mesylate in Patients with Chronic Myelogenous Leukemia: The Role of Uptake and Efflux Transporters","name":"articletitle","label":"Article Title"},{"value":"Current Therapeutic Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.curtheres.2022.100684","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100684"}}